The review synthesizes evidence on whether Alzheimer’s disease medications can improve neurocognitive outcomes in children ...
New research shows GRIN2A may be the first single gene capable of causing mental illness, challenging long-held beliefs about ...
Reports Major Clinical And Corporate Milestones As Phase 3 Alzheimer's Trial Advances Toward Completion. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it ...
Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...